{"product_id":"pavm-vrio-analysis","title":"PAVmed Inc. (PAVM): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to PAVmed Inc. (PAVM)'s long-term success starts here: our rigorous VRIO analysis distills whether its core assets truly deliver sustainable competitive advantage through Value, Rarity, Inimitability, and Organization. Discover the critical strengths - and potential weaknesses - that define PAVmed Inc. (PAVM)'s market position by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 1. Lucid Diagnostics EsoGuard Intellectual Property (IP)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core asset for PAVmed Inc. (PAVM) through the VRIO lens - that’s the EsoGuard Intellectual Property (IP) housed in its subsidiary, Lucid Diagnostics. The key takeaway here is that while the IP is valuable and currently rare, the competitive advantage is still provisional, hinging on how fast they can convert that unanimous Medicare support into actual dollars flowing into the bank.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Addressing a Critical Gap\u003c\/h3\u003e\n\u003cp\u003eThe value proposition is clear: EsoGuard is positioned as the first-and-only commercial tool for widespread, non-invasive early detection of esophageal precancer. This addresses a massive unmet need, given that esophageal adenocarcinoma mortality remains stubbornly high, often due to late-stage diagnosis via invasive endoscopy. Lucid Diagnostics confirmed this utility in their Q3 2025 update, reporting revenue of \u003cstrong\u003e$1.2 million\u003c\/strong\u003e from processing \u003cstrong\u003e2,841\u003c\/strong\u003e EsoGuard tests in that quarter alone. Real-world data backs this up, showing a \u003cstrong\u003e95%\u003c\/strong\u003e technical success rate for the EsoCheck collection device across nearly \u003cstrong\u003e12,000\u003c\/strong\u003e patients evaluated up to June 2024.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: A Unique Regulatory Milestone\u003c\/h3\u003e\n\u003cp\u003eThe combination of the FDA-cleared diagnostic test and the specific collection device is rare in the market right now. What makes it uniquely rare as of late 2025 is the regulatory traction. Lucid Diagnostics secured unanimous expert consensus for Medicare coverage following the Contractor Advisory Committee (CAC) meeting on September 4, 2025. This is a huge differentiator that most novel diagnostics struggle to achieve.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability: Investment and Regulatory Hurdles\u003c\/h3\u003e\n\u003cp\u003eImitating EsoGuard is moderately difficult. It requires not just significant R\u0026amp;D investment to develop the methylation-based assay but also navigating the complex, multi-year regulatory pathway, including the recent Medicare LCD process. Competitors are definitely trying, but the established clinical data and the regulatory precedent create a time-based barrier. Still, if a well-funded rival could replicate the science, the regulatory moat isn't impenetrable.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Capitalizing on Milestones\u003c\/h3\u003e\n\u003cp\u003eLucid Diagnostics has shown organizational capability in executing key financial and regulatory steps. They successfully raised capital, netting approximately \u003cstrong\u003e$27.0 million\u003c\/strong\u003e in a public offering during Q3 2025, which, combined with prior funds, extended their runway past 2026. This financial strengthening is crucial, especially considering PAVmed Inc.’s Q3 2025 GAAP net loss was \u003cstrong\u003e$6.3 million\u003c\/strong\u003e. The organization is clearly structured to push for reimbursement milestones.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for this IP asset:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eScore (1-4)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Implication\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes, addresses major unmet need (esophageal precancer detection).\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity (at minimum)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes, first-and-only commercial tool with recent unanimous Medicare support consensus.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eModerately costly and time-consuming to replicate due to R\u0026amp;D and regulatory history.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eYes, organization is structured to execute financing and regulatory milestones (e.g., $27.0M raise in Q3 2025).\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage: The Adoption Race\u003c\/h3\u003e\n\u003cp\u003eThe current advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. The unanimous support for Medicare coverage is a massive validation, but the sustained advantage isn't guaranteed yet. What this estimate hides is the speed of execution; the advantage only becomes sustained if Lucid Diagnostics can rapidly translate that coverage decision into widespread payer rollout and high-volume testing across the Medicare population. If onboarding takes 14+ days for new centers, churn risk rises.\u003c\/p\u003e\n\u003cp\u003eThe next step is clear: Finance needs to model the revenue impact assuming \u003cstrong\u003e50%\u003c\/strong\u003e Medicare adoption within 18 months of final LCD issuance. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 2. Veris Health Implantable Physiological Monitor Development\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe implantable physiological monitor is designed to interface with the Veris Cancer Care Platform to enhance personalized cancer care through continuous, real-time patient monitoring. This technology targets a segment of the \u003cstrong\u003e$120 billion\u003c\/strong\u003e global remote patient monitoring (RPM) market and aims to reduce unplanned hospitalizations, a \u003cstrong\u003e$30 billion\u003c\/strong\u003e cost center in oncology care.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe device concept involves an implantable monitor with biologic sensors, which is a distinct approach within the remote patient monitoring landscape.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdvancement through regulatory pathways for implantable devices requires significant capital investment, as evidenced by recent financing activities.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancing\/Funding Source\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eValuation Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Placement Equity Financing (June 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.5 million\u003c\/strong\u003e (gross and net)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$35 million\u003c\/strong\u003e pre-money valuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Financing (Earlier in 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eContributed to total 2025 funding of \u003cstrong\u003e$4.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH Grant\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNon-dilutive funding source\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDevelopment efforts have been relaunched, with specific regulatory targets set. The company has secured funding to support this progression.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDevelopment of the implantable physiological monitor has been fully relaunched.\u003c\/li\u003e\n\u003cli\u003eThe target for FDA submission is a planned \u003cstrong\u003e2026\u003c\/strong\u003e FDA 510(k) submission.\u003c\/li\u003e\n\u003cli\u003eThe monitor is designed to be implanted alongside a chemotherapy port.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is tied to being a first-mover with a differentiated, integrated device, contingent upon achieving regulatory milestones.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe financing structure includes warrants exercisable within \u003cstrong\u003e60 days\u003c\/strong\u003e of FDA clearance, linking future capital to regulatory success.\u003c\/li\u003e\n\u003cli\u003eThe planned FDA submission timeline is set for \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 3. Strategic Partnership with OSU-The James Cancer Hospital\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eStrategic Partnership with OSU-The James Cancer Hospital\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProvides a crucial, real-world clinical setting to deploy and validate the Veris Cancer Care Platform, driving commercial traction.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eA deep, commercial-phase partnership with a major academic cancer center like OSU-The James is not easily replicated.\u003c\/p\u003e\n\u003cp\u003eThe partnership involves an NCI-Designated Comprehensive Cancer Center.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh; requires trust, integration with EHR systems, and mutual commitment to patient care pathways.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAspect\u003c\/th\u003e\n\u003cth\u003eStatus\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership Phase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCommercial Phase\u003c\/strong\u003e launched on \u003cstrong\u003eOctober 7, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScope Expansion\u003c\/td\u003e\n\u003ctd\u003eExpanded from a pilot phase to a \u003cstrong\u003efull engagement\u003c\/strong\u003e across The James\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Registry\u003c\/td\u003e\n\u003ctd\u003eLaunching a \u003cstrong\u003eclinical registry\u003c\/strong\u003e on patients enrolled on the platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Integration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eElectronic health record (EHR) system integration\u003c\/strong\u003e is now in process\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the commercial phase launch in Q3 2025 shows the organization can execute on these complex collaborations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCommercial Phase Launch Date: \u003cstrong\u003eOctober 7, 2025\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePAVmed Q3 2025 GAAP net loss: \u003cstrong\u003e\\$6.3 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePAVmed Q3 2025 Operating expenses: approximately \u003cstrong\u003e\\$4.8 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePAVmed cash and cash equivalents as of September 30, 2025: \u003cstrong\u003e\\$3.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained; these deep clinical relationships become sticky and serve as a reference model for future centers.\u003c\/p\u003e\n\u003cp\u003eThe Veris Cancer Care Platform includes \u003cstrong\u003eremote physiological data collection\u003c\/strong\u003e via \u003cstrong\u003eVerisBox™\u003c\/strong\u003e devices with \u003cstrong\u003eembedded cellular connections\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 4. PAVmed Shared Services Model\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eAllows subsidiaries like Lucid and Veris to operate with lower overhead by leveraging centralized corporate functions, saving PAVmed \u003cstrong\u003e$27.3 million\u003c\/strong\u003e in operating expenses year-over-year (from \u003cstrong\u003e$42.3M\u003c\/strong\u003e to \u003cstrong\u003e$15M\u003c\/strong\u003e for 9M 2025). The shared services model directly impacts the parent company's reported operating expenses.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eOperating Expenses (GAAP)\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e9 Months Ended Sep 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$42.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9 Months Ended Sep 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$27.3 million\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.66 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.72 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e64%\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2024 (Non-GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.56 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 (Non-GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.43 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e65%\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerately rare; many smaller firms lack the established infrastructure to effectively centralize functions like finance and legal.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eModerate; competitors could build this, but it requires time and successful execution to prove its efficiency.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; management explicitly states they are leveraging this model to stabilize the corporate structure.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e'PAVmed, having stabilized its corporate structure and balance sheet, is well positioned to aggressively execute its strategic vision as a diversified commercial life sciences company with multiple independently-financed subsidiaries operating under a shared services model.'\u003c\/li\u003e\n\u003cli\u003e'PAVmed has stabilized its corporate structure, strengthened its balance sheet, and is positioned to advance its vision as a diversified commercial life sciences company with multiple independently-financed subsidiaries operating under a shared services model.'\u003c\/li\u003e\n\u003cli\u003e'So PAVmed is a vehicle to deliver innovative medical technologies, and we operate -- continue to operate under a shared services model.'\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; it provides a cost advantage now, but the parent company's own financial stability is the ultimate constraint.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSenior Secured Convertible Notes liability decreased from \u003cstrong\u003e$29.1 million\u003c\/strong\u003e at the end of 2024 to \u003cstrong\u003e$6.9 million\u003c\/strong\u003e by September 2025.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2025, were \u003cstrong\u003e$3.1 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$1.2 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eFor the nine months ended September 30, 2025, total revenue was \u003cstrong\u003e$19,000\u003c\/strong\u003e, down from \u003cstrong\u003e$2.985 million\u003c\/strong\u003e in the same period of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 5. Balance Sheet Deleveraging and Stabilization\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduced financial risk by cutting the Senior Secured Convertible Notes liability from \u003cstrong\u003e$29.1 million\u003c\/strong\u003e at the end of 2024 to \u003cstrong\u003e$6.9 million\u003c\/strong\u003e by September 2025. This reduction was achieved partly through a debt restructuring that exchanged approximately \u003cstrong\u003e80%\u003c\/strong\u003e of outstanding debt for Series C preferred equity. Furthermore, cash and cash equivalents increased from \u003cstrong\u003e$1.2 million\u003c\/strong\u003e as of December 31, 2024, to \u003cstrong\u003e$3.1 million\u003c\/strong\u003e as of September 30, 2025. Operating expenses for the first nine months of 2025 were reduced to \u003cstrong\u003e$15 million\u003c\/strong\u003e from \u003cstrong\u003e$42.3 million\u003c\/strong\u003e in the same period of 2024.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key balance sheet and operational expense metrics related to the deleveraging effort:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod End 2024 (Approximate)\u003c\/th\u003e\n\u003cth\u003eSeptember 30, 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSenior Secured Convertible Notes Liability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.2 million\u003c\/strong\u003e (Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9-Month Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$42.3 million\u003c\/strong\u003e (9M 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$15 million\u003c\/strong\u003e (9M 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorking Capital Position\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated\u003c\/td\u003e\n\u003ctd\u003eDeficiency of approximately \u003cstrong\u003e$6.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The significant reduction in the Senior Secured Convertible Notes liability to \u003cstrong\u003e$6.9 million\u003c\/strong\u003e is rare for a company in this developmental stage, where many peers carry higher debt burdens relative to their current operating scale. The Q3 2025 GAAP net loss attributable to common stockholders was \u003cstrong\u003e$6.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; achieving this level of debt reduction required disciplined cash management, including a reported Q3 operating expense of approximately \u003cstrong\u003e$4.8 million\u003c\/strong\u003e, and strategic financing decisions such as a public offering that netted approximately \u003cstrong\u003e$27.0 million\u003c\/strong\u003e in proceeds during Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this was a stated priority over the last 18 months, with management actively engaging in a multi-step process to stabilize the balance sheet, including deconsolidating Lucid from PAVmed's consolidated financial statements.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while the deleveraging was crucial for immediate stability, management disclosed “substantial doubt” about the company's ability to continue as a going concern, and plans to explore additional capital raising opportunities suggest this stability is contingent upon future financing success.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eGAAP net loss attributable to common stockholders for the nine months ending September 30, 2025, was approximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 revenue was reported as \u003cstrong\u003e$5 thousand\u003c\/strong\u003e, with year-to-date revenue at \u003cstrong\u003e$19 thousand\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 6. Lucid Diagnostics Commercialization Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The established team and processes that allowed Lucid to recognize \u003cstrong\u003e$1.2 million\u003c\/strong\u003e in EsoGuard revenue in Q3 2025 from \u003cstrong\u003e2,841\u003c\/strong\u003e tests processed.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEsoGuard Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 recognized revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests Processed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,841\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLucid Proforma Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$47.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAC Meeting Outcome\u003c\/td\u003e\n\u003ctd\u003eUnanimous Support\u003c\/td\u003e\n\u003ctd\u003eSeptember 4, 2025, for Medicare LCD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; building a dedicated commercial sales and market access team for a novel diagnostic takes time and specific expertise.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can hire similar talent, but the learned experience of scaling EsoGuard is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the team is focused on payor engagement to accelerate coverage post-CAC support.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eLucid Diagnostics ended Q3 2025 with over \u003cstrong\u003e$47 million\u003c\/strong\u003e in proforma cash, extending runway through 2026.\u003c\/li\u003e\n\u003cli\u003eRecruited world-class market access team focused on payor engagement, broad insurance coverage, and patient access.\u003c\/li\u003e\n\u003cli\u003eInitiated patient testing and billing under first positive commercial insurance coverage policy from Highmark Blue Cross Blue Shield, effective May 26, 2025.\u003c\/li\u003e\n\u003cli\u003eLucid Diagnostics Q3 2025 GAAP net loss attributable to common stockholders was approximately \u003cstrong\u003e$10.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; success hinges on converting the CAC support into broad, profitable insurance coverage quickly.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 7. New Technology Licensing Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ability to quickly evaluate and secure rights to new, potentially disruptive technologies, like the recently signed LOI for endoscopic esophageal imaging. Prior clinical research showed the a\/LCI + OCT technology demonstrated 100% sensitivity and 88% overall accuracy when used alone in detecting precancerous changes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the willingness and structure to spin up new subsidiaries for licensing deals is a specific strategic choice. This model builds on the successful academic medical center partnership model that launched Lucid Diagnostics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a function of management's deal-making network and strategic vision. The company is executing a strategy of independently financeable subsidiaries operating under a shared services infrastructure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the LOI shows the structure is ready to absorb new pipeline assets immediately. As of September 30, 2025, PAVmed reported cash and cash equivalents of $3.1 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; if management consistently finds and licenses undervalued IP, this becomes a core strength. The company's recent financial results show a Non-GAAP adjusted loss of approximately $0.4 million for Q3 2025.\u003c\/p\u003e\n\u003cp\u003eThe execution of the licensing strategy is evidenced by the progression of existing and new ventures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe new endoscopic imaging technology is being licensed through a newly-formed subsidiary.\u003c\/li\u003e\n\u003cli\u003eThe existing subsidiary, Lucid Diagnostics, recognized $1.2 million in EsoGuard® revenue for Q3 2025, processing 2,841 tests.\u003c\/li\u003e\n\u003cli\u003ePAVmed's ownership in Lucid Diagnostics is 23% ownership and 28% voting interest.\u003c\/li\u003e\n\u003cli\u003eThe company previously conducted a 1-for-15 reverse stock split effective December 7, 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eNew Endoscopic Imaging Venture (LOI)\u003c\/td\u003e\n\u003ctd\u003eLucid Diagnostics (Established Model)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Focus\u003c\/td\u003e\n\u003ctd\u003ea\/LCI + OCT Probe for Real-Time Dysplasia Detection\u003c\/td\u003e\n\u003ctd\u003eEsoGuard DNA Test \u0026amp; EsoCheck Collection Device\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\/Origin\u003c\/td\u003e\n\u003ctd\u003eDuke University and UNC\u003c\/td\u003e\n\u003ctd\u003eCWRU (Amended License terminates May 12, 2038, or patent expiration)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue (Context)\u003c\/td\u003e\n\u003ctd\u003eNot yet applicable (LOI stage)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.2 million\u003c\/strong\u003e in revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Test Volume\u003c\/td\u003e\n\u003ctd\u003eNot yet applicable (LOI stage)\u003c\/td\u003e\n\u003ctd\u003e2,841 tests processed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubsidiary Structure\u003c\/td\u003e\n\u003ctd\u003eTo be developed within a newly-formed subsidiary\u003c\/td\u003e\n\u003ctd\u003ePAVmed holds 23% ownership\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 8. Diversified Sector Presence (Device, Diagnostics, Digital Health)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Mitigates risk by not relying on a single product; success in one subsidiary (like Lucid) can fund development in another (like Veris).\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe structure allows for independent financing and operational focus, as evidenced by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLucid Diagnostics securing capital to extend runway well past key reimbursement milestones, ending 1Q25 with over \u003cstrong\u003e$40 million\u003c\/strong\u003e in proforma cash.\u003c\/li\u003e\n\u003cli\u003eVeris Health completing 1Q25 financing at a \u003cstrong\u003e$35 million\u003c\/strong\u003e pre-money valuation.\u003c\/li\u003e\n\u003cli\u003ePAVmed's overall operating expenses decreasing from \u003cstrong\u003e$42.3 million\u003c\/strong\u003e in the first nine months of 2024 to \u003cstrong\u003e$15 million\u003c\/strong\u003e in the same period of 2025, reflecting the deconsolidation and independent financing strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Rare for a company of this size; most focus on one vertical.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe simultaneous operation across three distinct, commercially active or advancing verticals is uncommon for a company with PAVmed's scale, as shown by:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDiagnostics (Lucid)\u003c\/th\u003e\n\u003cth\u003eDigital Health (Veris)\u003c\/th\u003e\n\u003cth\u003eParent (PAVM) Overall\u003c\/th\u003e\n\u003cth\u003eDevice (PMX Incubator)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Quarterly GAAP Revenue Contribution (PAVM)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Deconsolidated)\u003c\/td\u003e\n\u003ctd\u003eSubscription Revenues Recognized\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5,000\u003c\/strong\u003e (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A (PortIO in discussions)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Test Volume\/Patient Count\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,756\u003c\/strong\u003e EsoGuard Tests Processed (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e125\u003c\/strong\u003e patients on Platform (Q4 2024)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Reported Cash Position\u003c\/td\u003e\n\u003ctd\u003eN\/A (Reported on Proforma basis for Lucid)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.1 million\u003c\/strong\u003e (Sept 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Revenue (2024)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Revenue reported separately)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Revenue reported separately)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2,995 thousand\u003c\/strong\u003e (Total GAAP)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High; requires the ability to manage vastly different regulatory and commercial pathways simultaneously.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe complexity is demonstrated by the varied milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiagnostics (Lucid): Securing commercial insurance coverage policies for EsoGuard.\u003c\/li\u003e\n\u003cli\u003eDigital Health (Veris): Resuming development of implantable physiological monitor through \u003cstrong\u003eFDA\u003c\/strong\u003e clearance.\u003c\/li\u003e\n\u003cli\u003eDevice (PMX Incubator): Advancing PortIO through direct investment financing discussions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the entire corporate structure is built around this diversified, subsidiary-based approach.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe structure is explicitly designed around shared services:\u003c\/p\u003e\n\u003cp\u003eThe shared, enabling functions allow PAVmed to achieve economies of scale and rapidly deploy resources across its businesses.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; this structural diversification is hard to unwind and provides a buffer against single-product failure.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe financial buffer effect is seen in the year-over-year expense management:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperating Expenses for the nine months ended September 30, 2024, were \u003cstrong\u003e$42.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating Expenses for the nine months ended September 30, 2025, were reduced to \u003cstrong\u003e$15 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe fair value of the investment in Lucid Diagnostics was \u003cstrong\u003e$31.6 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePAVmed Inc. (PAVM) - VRIO Analysis: 9. Veris Health Cancer Care Platform (Software\/Services)\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eOffers recurring revenue potential, reflected in Q1 2025 revenues which included subscription revenues from the Veris Cancer Care Platform. Value-add services include AI-based risk stratification tools beyond just hardware monitoring. The platform seeks to reduce unplanned hospitalizations and provide data-driven risk management tools.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; while Remote Patient Monitoring (RPM) is common, the integration with an implantable device, designed to be implanted alongside a chemotherapy port, and AI tools is less common. The implantable monitor's passive data collection and oncology specificity create a niche.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eModerate; competitors have Electronic Health Record (EHR) integration, but the specific clinical decision support tools are proprietary. The development of the implantable physiological monitor is targeted for an FDA 510(k) submission in 2026.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eModerate; the focus is shifting from pure RPM to broader clinical support services. Veris Health has raised capital at a $35 million pre-money valuation, supplementing a $1.8 million NIH grant and a pilot partnership with The Ohio State University's James Cancer Hospital.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; the platform's value is tied to the adoption of the implantable monitor, which is still in development, with FDA clearance targeted for 2026.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Element\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSubscription Revenue Recognized in Q1 2025; AI Risk Stratification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eImplantable Monitor Integration; Oncology Specificity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eProprietary Clinical Decision Support Tools; Planned 2026 FDA Submission\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eSecured $\\mathbf{\\$4.9}$ million in funding at $\\mathbf{\\$35}$ million pre-money valuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eDependent on Implantable Monitor Adoption Post-$\\mathbf{2026}$ Clearance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: Draft 13-Week Cash Flow Projection Incorporating Potential Capital Raising by Friday\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProjected 13-Week Cash Flow Summary (Illustrative)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStarting Cash (Week 0, as of 9\/30\/2025):\u003c\/strong\u003e $\\mathbf{\\$3.1}$ million\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEstimated Weekly Operating Cash Outflow (Proxy based on Q3 2025 OpEx of $\\mathbf{\\$4.8}$ million over $\\sim 13$ weeks):\u003c\/strong\u003e $\\sim \\mathbf{\\$369,231}$\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTotal Projected Operating Cash Outflow (13 Weeks):\u003c\/strong\u003e $\\sim \\mathbf{\\$4.8}$ million\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProjected Cash Balance End of Week 13 (Before Financing):\u003c\/strong\u003e $\\sim -\\mathbf{\\$1.7}$ million\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDraft 13-Week Cash Flow Projection Table (Amounts in USD)\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek Ending\u003c\/td\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003eNet Cash Flow (Operations)\u003c\/td\u003e\n\u003ctd\u003eNet Cash Flow (Financing - Hypothetical Friday Raise)\u003c\/td\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 1 (Friday)\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{3,100,000}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{5,000,000}$ (Hypothetical Raise)\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{7,730,769}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{7,730,769}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{7,361,538}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{7,361,538}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{6,992,307}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 4\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{6,992,307}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{6,623,076}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 5\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{6,623,076}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{6,253,845}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 6\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{6,253,845}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{5,884,614}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 7\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{5,884,614}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{5,515,383}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 8\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{5,515,383}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{5,146,152}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 9\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{5,146,152}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{4,776,921}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 10\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{4,776,921}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{4,407,690}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 11\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{4,407,690}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{4,038,459}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 12\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{4,038,459}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{3,669,228}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{3,669,228}$\u003c\/td\u003e\n\u003ctd\u003e$\\sim -369,231$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{3,300,000}$ (Approximate)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516227313813,"sku":"pavm-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/pavm-vrio-analysis.png?v=1740204465","url":"https:\/\/dcf-model.com\/fr\/products\/pavm-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}